lonigutamab ugodotin

N/A

Report date: 2024/12/11 20:00:45

Base Information

Drug Namelonigutamab ugodotin

Drug Alias NameW-0101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > F554443 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionInsulin-like growth factor I receptor antagonists

TargetsInsulin-like growth factor I receptor

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFranceSpain

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPierre Fabre Group

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPierre Fabre Medicament

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A